Compared with monotherapy, DAPT reduced the risk of recurrent stroke (RR, 0.71 [95% CI, 0.63-0.81]) and composite outcome (RR, 0.76 [95% CI, 0.69-0.83]) but increased the risk of major bleeding (RR, 2.17 [95% CI, 1.45-3.25]).
22 июн. 2021 г.
Efficacy and Safety of Using Dual Versus Monotherapy ... www.ahajournals.org › doi › CIRCULATIONA...
30 апр. 2021 г. · DAPT decreases the risk of recurrent stroke and composite events compared with monotherapy. DAPT increases the risk of major hemorrhage, except ... |
1 мая 2024 г. · This systematic review and meta-analysis found that ticagrelor monotherapy was noninferior to DAPT for all-cause death, MI, or stroke and ... |
25 июн. 2019 г. · This randomized noninferiority trial compares the effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy (DAPT) on cardiac and ... |
Conclusions. P2Y12 inhibitor monotherapy, specifically with ticagrelor is superior to standard dual antiplatelet therapy (DAPT) in reducing both all-cause and ... |
17 апр. 2024 г. · This randomized clinical trial evaluates clopidogrel monotherapy vs dual antiplatelet therapy in patients with acute coronary syndromes ... |
12 мая 2021 г. · After minor ischemic stroke, short-term (≤30 days) DAPT is superior to MAPT in preventing recurrent stroke. The results of this study suggest ... |
14 февр. 2023 г. · We sought to assess the effects of P2Y12 inhibitor monotherapy after 1-month to 3-month DAPT vs standard DAPT in relation to PCI complexity. Skip main navigation · Results · Discussion · Conclusions |
| Novbeti > |
| Axtarisha Qayit Anarim.Az Anarim.Az Sayt Rehberliyi ile Elaqe Saytdan Istifade Qaydalari Anarim.Az 2004-2023 |